Skip to main content
Howard Covel

Featured Patient Story

Howard Covel

Where will this ATTRwt amyloidosis journey take me? I like to travel; however, this trip was not planned or wanted!  I wonder a lot about the journey I am starting, so far it has been OK.

read more

Latest News Story Headlines

Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Nov 25, 2024

− Prescription Drug User Fee Act (PDUFA) Date Set for March 23, 2025 −

read full article
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

11.22.2024 at 7:12 PM EST

read full article
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

CAMBRIDGE, Mass., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.

read full article

Calendar & Upcoming Events

Webinar: Grace vs. Forgiveness

Webinar Session, Wednesday, Dec. 4th, 2024 at 6 PM (ET)

view all event details

Amyloidosis Videos

Our Latest Webinar

Updates in AL amyloidosis: Fast Forward in 2024!

Heather Landau, MD - Memorial Sloan Kettering Cancer Center - New York, NY

Sign Up for the Latest Updates

Get news from Amyloidosis Foundation
in your inbox

By submitting this form, you are consenting to receive marketing emails from : Amyloidosis Foundation, 7151 N. Main St., Suite 2, Clarkston, MI, 48346, US, https://www.amyloidosis.org. You can revoke your consent to receive emails at any time by using SafeUnsubscribe© link, found at the bottom of every email. Emails are serviced by Constant Contract.